MARKET RESEARCH ON USAGE OF ANTIBIOTICS IN SERIOUS INFECTIONS
Objective: The main objective of the study is to prognosticate the market research on usage of antibiotics in serious infections and corresponding with the clinicians based on the preference order of drugs.
Methods: A prospective observational study was conducted for a period of six months in various hospitals in AndhraPradesh. Analysis on Piperacillin + Tazobactum, Cefepime and Meropenem drugs used for resistant isolates were identified to be the most effective antibacterial agents. Respondents reviewed three drugs based on the dosage, duration, type of case and any specific conditions to avoid these drugs.
Results: Out of total Sample size (N=128) when assessed Piperacillin+Tazobactum (84.38%), Cefepime (12.50%), Meropenem (3.12%). The most prevalent type of case and usage of doctors to treat UTI (25.00%), Sepsis (17.86%), Severe Sepsis (14.29%), CRTI, LRTI (8.33%) and others (34.52%) were reported.
Conclusion: Piperacillin+Tazobactum is used as Ist line, Cefepime as IInd line followed by Meropenem as IIIrd line drug. When a competitor enters the market they should consider the availability of the products (domestic & generic) as per the cost effectiveness reliable to the patients which has lesser side effects, antibiotic resistance and ease for intake to the patients as per the demographical conditions is observed.
Keywords: N- respondents (doctors), UTI, CRTI, LRTI, Sepsis, Antibiotic Resistance and Competitor.
2. ls Merrem IV, Wilmington DE. Astra Zeneca Pharmaceutica(Meropenem) injection for intravenous use only prescribing information. May. 2005.
3. Wiseman RL, Balch WE. A new pharmacology-drugging stressed folding pathways. J Trends Mol Med 2005;11(8):347-50.
4. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. J Drugs 1995;50(1):73-101.
5. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clinical infectious diseases:an official publication. J Infectious Diseases Society of America 2004;39(9):1267-84.
6. Goldstein SL, Murry DJ, May S, Aleksic A, Sowinski KM, Blaney S. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. J Pediatric Nephrology (Berlin, Germany) 2001;16(12):1015-8.
7. Angelescu M, Apostol A. Chirurgia. 2001 Nov-Dec;96(6):547-52. Review. Romanian. J Pub Med PMID 12731231.
8. Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. J Antimicrob Agents Chemother 1992;36(3):552-7.
9. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. J Clin Pharmacol Ther 1990;48(3):268-76.
10. Nccls, Villanova PA. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility. J Tests Fifth Edition Approved Standard Vol No 24 NCCLS December 1993;13:M2-A5.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. J Nephron 1976;16(1):31-41.
12. Schoonover LL, Occhipinti DJ, Rodvold KA, Danziger LH. Piperacillin/tazobactam:a new beta-lactam/beta-lactamase inhibitor combination. J The Annals of pharmacotherapy 1995;29(5):501-14.
13. Weler DA, Sanders CC. Diverse potential of [tamase inhibitors to induce class enzymes. J Antimicrobal Agents Chemother 156158. 1995;34:3-1ac.
14. M. T, Tan JS. File Efficacy and safety of piperacillin/Tazobactam in skin and soft tissue infections. J Eur Surg 573 Suppl 1994:51-5.
15. E. W, Sanders CC. Sanders Piperacillin/Tazobactam:A critical review of the evolving clinical literature. J Clin Infect Dis 1996;22:107-12.